levodopa and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Mapping; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Stereotaxic Techniques; Thalamus

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Diseases; Bromocriptine; Dopamine; Humans; Hydroxydopamines; Injections, Intraperitoneal; Levodopa; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Pergolide; Primates; Pyridines; Receptors, Dopamine; Substance Withdrawal Syndrome

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biopterins; Dopamine Agents; Droxidopa; Humans; Levodopa; Nerve Tissue; Parkinson Disease; Pyridines; Serine

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Antiparkinson Agents; Carbidopa; Dopamine; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine; Ergolines; Humans; Levodopa; Macaca mulatta; Neural Pathways; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Quinpirole; Rats; Saimiri; Selegiline; Species Specificity; Substantia Nigra

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Deoxyglucose; Haplorhini; Humans; Levodopa; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Spiperone

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Benserazide; Clorgyline; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Phenethylamines; Pyridines; Selegiline; Stereoisomerism

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzylamines; Dopamine; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Norepinephrine; Parkinson Disease, Secondary; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Dementia; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Primates; Psychoses, Substance-Induced; Pyridines; Receptors, Dopamine; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Basal Ganglia; Brain Tissue Transplantation; Caudate Nucleus; Fetal Tissue Transplantation; Fluorine Radioisotopes; Humans; Levodopa; Magnetic Resonance Imaging; Mesencephalon; Parkinson Disease; Parkinson Disease, Secondary; Putamen; Tomography, Emission-Computed; Transplantation, Heterotopic; Treatment Outcome

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aging; Antiparkinson Agents; Antipsychotic Agents; Calcium Channel Blockers; Humans; Levodopa; Psychomotor Disorders

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cognition; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Levodopa; Macaca fascicularis; Male; Motor Activity; Nicotinic Agonists; Pyridines; Pyrrolidines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agonists; Drug Resistance; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinsonian Disorders; Primates

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catechols; Disease Models, Animal; Dopamine Agonists; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Nitriles; Parkinson Disease, Secondary; Primates; Rats

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Globus Pallidus; Humans; Levodopa; Movement Disorders; Neurons; Neurosurgical Procedures; Oxidopamine; Parkinson Disease; Treatment Failure

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Primates

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Female; Fetal Tissue Transplantation; Humans; Immunosuppression Therapy; Levodopa; Male; Mesencephalon; Motor Activity; Parkinson Disease, Secondary; Putamen; Stereotaxic Techniques; Time Factors; Tomography, Emission-Computed

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Clinical Trials as Topic; Designer Drugs; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Selegiline; Substantia Nigra

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Random Allocation; Selegiline

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Models, Theoretical; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Selegiline

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Aged; Clinical Trials as Topic; Double-Blind Method; Humans; Levodopa; Models, Neurological; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Prospective Studies; Pyridines; Pyridinium Compounds; Selegiline

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arm; Behavior, Animal; Carbidopa; Female; Levodopa; Macaca mulatta; Male; Movement; Parkinson Disease, Secondary; Reaction Time; Substantia Nigra; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Catecholamines; Dopamine; Dopamine Agents; Levodopa; Macaca fascicularis; Male; Mazindol; Parkinson Disease, Secondary; Receptors, Dopamine

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2-Amino-5-phosphonovalerate; Animals; Callithrix; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Motor Activity; N-Methylaspartate

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Callithrix; Dopamine Agents; Ergolines; Female; Levodopa; Male; Movement; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Estradiol; Female; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Progesterone

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Corpus Striatum; Dopamine; Female; Levodopa; Macaca mulatta; Parkinson Disease, Secondary; Radiochemistry; Structure-Activity Relationship; Tomography, Emission-Computed

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamines; Animals; Apomorphine; Benserazide; Carboxy-Lyases; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Parkinson Disease, Secondary

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Deoxyglucose; Female; Globus Pallidus; Levodopa; Macaca fascicularis; Male; Parkinson Disease; Thalamic Nuclei

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; In Vitro Techniques; Isoproterenol; Levodopa; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary; Receptors, Adrenergic, beta; Synapses

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analysis of Variance; Animals; Callithrix; Disease Models, Animal; Drug Synergism; Ibotenic Acid; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Piperazines; Quinoxalines; Rats; Rats, Inbred Strains; Receptors, N-Methyl-D-Aspartate; Substantia Nigra

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Autoradiography; Brain; Bromocriptine; Carbidopa; Catecholamines; Dopamine Agents; Female; Levodopa; Macaca fascicularis; Receptors, Dopamine; Spiperone

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Cutaneous; Animals; Antiparkinson Agents; Athetosis; Chorea; Dopamine Agents; Levodopa; Oxazines; Saimiri

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callitrichinae; Dopamine; Dopamine Agents; Excitatory Amino Acid Antagonists; Female; Levodopa; Male; Neurotransmitter Agents; Parasympathomimetics; Parkinson Disease, Secondary; Receptors, Neurotransmitter; Serotonin Antagonists

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Benzylamines; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Nerve Endings; Neurotoxins; Norepinephrine

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Attention; Behavior, Animal; Female; Levodopa; Macaca fascicularis; Macaca mulatta; Motor Activity; Parkinson Disease, Secondary; Reaction Time; Visual Perception

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Levodopa; Macaca mulatta; Neurologic Examination; Parkinson Disease, Secondary; Stereotyped Behavior

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cerebral Cortex; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Injections, Subcutaneous; Levodopa; Locomotion; Male; Mice; Mice, Inbred Strains; Motor Activity; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; Benzazepines; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxazines; Parkinson Disease, Secondary; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Saimiri

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Injections, Intravenous; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary; Receptors, Dopamine; Tyrosine

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Brain; Brain Chemistry; Bromocriptine; Dopamine; Female; Homovanillic Acid; Kinetics; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary; Receptors, Dopamine; Spiperone

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Body Weight; Corpus Striatum; Disease Models, Animal; Dopamine; Hydrazines; Levodopa; Male; Methyltyrosines; Mice; Mice, Inbred C57BL; Motor Activity; Parkinson Disease, Secondary; Receptors, Dopamine; Stereotyped Behavior

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Anesthesia; Animals; Benzamides; Benzazepines; Carbidopa; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Halothane; Kinetics; Levodopa; Mice; Mice, Inbred C57BL; Receptors, Dopamine

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Carbidopa; Corpus Striatum; Deoxyglucose; Flunitrazepam; gamma-Aminobutyric Acid; Globus Pallidus; Levodopa; Macaca fascicularis; Neurons; Organ Specificity; Parkinson Disease; Parkinson Disease, Secondary; Tritium

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Apomorphine; Behavior, Animal; Carbidopa; Caudate Nucleus; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Macaca mulatta; Motor Activity; Parkinson Disease; Sural Nerve; Transplantation, Heterotopic

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease, Secondary; Saimiri; Sincalide

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chorea; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Saimiri

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amines; Brain; Bromocriptine; Catecholamines; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Prolactin; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Analgesics; Animals; Callitrichinae; Dopamine Agents; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Phenanthridines; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Ergolines; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Quinpirole

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinson Disease, Secondary; Prodrugs; Saimiri; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Dose-Response Relationship, Drug; Ergolines; Injections, Intravenous; Levodopa; Macaca fascicularis; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Quinpirole; Stereotyped Behavior

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Methyltyrosine; Animals; Dopamine; Levodopa; Male; Methyltyrosines; Mice; Neurons; Pyridines; Receptors, Dopamine; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Levodopa; Macaca fascicularis; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Droxidopa; Levodopa; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary; Pyridines; Receptors, Muscarinic; Somatostatin

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Oxazines; Parkinson Disease, Secondary; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callitrichinae; Female; Isomerism; Levodopa; Male; Motor Activity; Piperidines; Pyridines; Receptors, Dopamine; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Antiparkinson Agents; Brain; Dopamine; Droxidopa; Humans; Levodopa; Norepinephrine; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Serine; Stereotaxic Techniques

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Basal Ganglia; Benserazide; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease; Phenethylamines; Pyridines; Selegiline

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Humans; Indans; Isoenzymes; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Selegiline; Structure-Activity Relationship; Tyramine

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Callitrichinae; Catalepsy; Dopamine; Dopamine Antagonists; Haloperidol; Injections; Ketotifen; Levodopa; Male; Motor Activity; Nucleus Accumbens; Pyridines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Carbidopa; Disease Models, Animal; Drug Combinations; Electromyography; Levodopa; Macaca mulatta; Movement Disorders; Parkinson Disease, Secondary; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Eye Movements; Female; Glucose; Levodopa; Macaca mulatta; Male; Oculomotor Muscles; Parkinson Disease, Secondary; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Histocytochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Microscopy, Fluorescence; Parkinson Disease, Secondary; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Electroretinography; Evoked Potentials, Visual; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Pyridines; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dementia; Female; Humans; Levodopa; Male; Mice; Middle Aged; Oxygen; Parkinson Disease; Pyridines; Serotonin; Tryptophan Hydroxylase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Homovanillic Acid; Infusion Pumps; Injections, Spinal; Levodopa; Parkinson Disease, Secondary; Pyridines; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Catecholamines; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Hypothalamic Area, Lateral; Levodopa; Macaca fascicularis; Male; Mice; Mice, Inbred C57BL; Motor Activity; Motor Skills; Neural Pathways; Psychomotor Performance; Pyridines; Substantia Nigra

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Equipment Design; Feeding Behavior; Levodopa; Macaca fascicularis; Male; Movement; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Rats

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Brain; Brain Chemistry; Carbidopa; Carotid Artery, Internal; Disease Models, Animal; Dominance, Cerebral; Dopamine; Homovanillic Acid; Injections, Intra-Arterial; Levodopa; Macaca fascicularis; Movement; Neurons; Parkinson Disease, Secondary; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Bromocriptine; Butyrophenones; Female; Kinetics; Levodopa; Macaca fascicularis; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Spiperone; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Bromocriptine; California; Chemical Industry; District of Columbia; Female; Humans; Levodopa; Male; Occupational Diseases; Parkinson Disease, Secondary; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Levodopa; Parkinson Disease; Pyridines; Research; Substantia Nigra

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cysteinyldopa; Delayed-Action Preparations; Dopamine; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Structure-Activity Relationship

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Electromyography; Levodopa; Macaca mulatta; Parkinson Disease, Secondary; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Fetus; Levodopa; Macaca mulatta; Mesencephalon; Motor Activity; Parkinson Disease, Secondary; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Female; Glucose; Levodopa; Macaca mulatta; Male; Parkinson Disease, Secondary; Pyridines; Tissue Distribution

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Levodopa; Male; Mice; Mice, Inbred C57BL; Pyridines; Quinuclidinyl Benzilate; Receptors, Muscarinic

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Adult; Carbidopa; Chronic Disease; Drug Combinations; Female; Humans; Levodopa; Male; Parkinson Disease; Pyridines; Substance-Related Disorders; Substantia Nigra

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Bromocriptine; Corpus Striatum; Dopamine; Haloperidol; Levodopa; Male; Mice; Mice, Inbred C57BL; Nomifensine; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biogenic Amines; Brain Chemistry; Bromocriptine; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Movement; Parkinson Disease, Secondary; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Disease Models, Animal; Dopamine; Levodopa; Mice; Mice, Inbred C57BL; Motor Activity; Norepinephrine; Parkinson Disease, Secondary; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Benserazide; Benzazepines; Callitrichinae; Levodopa; Male; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Tremor

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Disease Models, Animal; Dopamine; Female; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Macaca mulatta; Male; Neurons; Parkinson Disease; Posture; Pyridines; Substantia Nigra

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Callitrichinae; Caudate Nucleus; Dopamine; Female; Homovanillic Acid; Levodopa; Parkinson Disease, Secondary; Putamen; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Carbidopa; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Parkinson Disease, Secondary; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Callithrix; Caudate Nucleus; Enkephalins; Female; Gene Expression; In Situ Hybridization; Levodopa; Male; Mazindol; Motor Activity; Nucleus Accumbens; Putamen; RNA, Messenger; Substance P

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Cholecystokinin; Dopamine; Levodopa; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neuropeptides; Radioimmunoassay; Substance P; Thyrotropin-Releasing Hormone

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aminoquinolines; Animals; Autoradiography; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Imidazoles; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, GABA

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; Animals; Apomorphine; Biogenic Monoamines; Dopamine; Dopamine Agents; Dopamine Antagonists; Hydroxyindoleacetic Acid; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Rats; Rats, Wistar; Stereotyped Behavior; Tryptophan

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Carbidopa; Catecholamines; Disease Models, Animal; Drug Combinations; Humans; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Azepines; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Injections, Intraperitoneal; Injections, Intravenous; Injections, Subcutaneous; Levodopa; Male; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2-Amino-5-phosphonovalerate; Animals; Behavior, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; N-Methylaspartate; Receptors, N-Methyl-D-Aspartate; Stereoisomerism

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; G(M1) Ganglioside; Levodopa; Macaca fascicularis; Neurons; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cholinergic Antagonists; Electric Stimulation; Electrophysiology; Evoked Potentials, Somatosensory; gamma-Aminobutyric Acid; Levodopa; Macaca fascicularis; Median Nerve; Norepinephrine; Parkinson Disease, Secondary; Receptors, N-Methyl-D-Aspartate

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids; Animals; Blood-Brain Barrier; Female; Levodopa; Macaca fascicularis; Macaca mulatta; Male; Parkinson Disease, Secondary

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Carbidopa; Corpus Striatum; Dopamine Agents; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Macaca fascicularis; Parkinson Disease, Secondary; Psychomotor Performance; Receptors, Dopamine D1; Receptors, Dopamine D2

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Catecholamines; Cognition; Dopamine; Dopamine Agents; Habituation, Psychophysiologic; Levodopa; Male; Memory; Mice; Social Behavior

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Atropine; Baclofen; Clonidine; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Meperidine; Methoxydimethyltryptamines; Neurotransmitter Agents; Yohimbine

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetamides; Analysis of Variance; Animals; Anticonvulsants; Antiparkinson Agents; Brain; Carbidopa; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Combinations; Levodopa; Macaca mulatta; Male; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reserpine; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Drug Implants; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; MPTP Poisoning; Neurotoxins; Orchiectomy; Parkinson Disease, Secondary; Reference Values; Species Specificity; Testosterone

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Benzazepines; Brain; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Receptors, Dopamine D1; Receptors, Dopamine D2; Spiperone

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Callithrix; Dialysis; Drug Interactions; Female; Levodopa; Locomotion; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Picolinic Acids

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Activities of Daily Living; Adult; Brain Tissue Transplantation; Dominance, Cerebral; Female; Fetal Tissue Transplantation; Follow-Up Studies; Gait; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Neurologic Examination; Parkinson Disease, Secondary

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Carotid Arteries; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Feeding Behavior; Female; Injections, Intra-Arterial; Levodopa; Macaca mulatta; Motor Activity; Parkinson Disease, Secondary

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Benzazepines; Bromocriptine; Corpus Striatum; Cycloheximide; Dopamine Antagonists; Haloperidol; Kinetics; Levodopa; Male; Mice; Pyridoxal Phosphate; Receptors, Dopamine; Reserpine; Sulpiride; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; G(M1) Ganglioside; Levodopa; Mice; Mice, Inbred C57BL; Neurons; Parkinson Disease; Substantia Nigra

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Autoradiography; Basal Ganglia; Brain; Cell Death; Humans; Iodine Radioisotopes; Levodopa; Macaca fascicularis; Nerve Degeneration; Neurons; Parkinson Disease; Radioligand Assay; Receptors, Transferrin; Reference Values

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Chorea; Dyskinesia, Drug-Induced; Dystonia; Excitatory Amino Acid Antagonists; Female; Isoquinolines; Levodopa; Macaca fascicularis; Macaca mulatta; Male; Parkinson Disease, Secondary; Receptors, N-Methyl-D-Aspartate

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Female; Globus Pallidus; Glutamate Decarboxylase; Humans; In Situ Hybridization; Levodopa; Macaca fascicularis; Male; Parkinson Disease, Secondary; RNA, Messenger; Substantia Nigra

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; Callithrix; Carbidopa; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Neurologic Examination; Parkinson Disease, Secondary

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Brain; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Skills; Neurologic Examination; Parkinson Disease, Secondary; Receptors, Dopamine D1

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Glutamate Decarboxylase; Levodopa; Macaca; Putamen; X-Rays

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Basal Ganglia; Callithrix; Dopamine Agents; Female; Levodopa; Male; Receptors, Dopamine D2; Receptors, Dopamine D3; Tissue Distribution

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Mapping; Carbidopa; Female; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Parkinson Disease, Secondary

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromocriptine; Cell Count; Levodopa; Mice; Mice, Inbred C57BL; Substantia Nigra

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Brain; Brain Diseases; Dopamine Agents; Female; Humans; In Situ Hybridization; Levodopa; Macaca fascicularis; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dominance, Cerebral; Electric Stimulation Therapy; Electromyography; Levodopa; Macaca mulatta; Motor Skills; Neurologic Examination; Parkinson Disease, Secondary; Thalamic Nuclei

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Cabergoline; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Hyperkinesis; Levodopa; Macaca fascicularis; Movement; Parkinson Disease, Secondary

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Brain Mapping; Caudate Nucleus; Corpus Striatum; Dopamine; Female; Levodopa; Macaca fascicularis; Male; Parkinson Disease, Secondary; Putamen; Receptors, Dopamine D1

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzophenones; Catechol O-Methyltransferase; Disease Models, Animal; Enzyme Inhibitors; Levodopa; Macaca mulatta; Nitrophenols; Parkinson Disease; Tolcapone

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alpha-Globulins; Animals; Antiparkinson Agents; Brain; Glycoproteins; Injections, Intraventricular; Levodopa; Male; Mice; Parkinson Disease, Secondary

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Carbidopa; Dopamine Antagonists; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Piperidines; Posture; Raclopride; Salicylamides

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Cerebral Ventricles; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Female; Glial Cell Line-Derived Neurotrophic Factor; Injections, Intraventricular; Levodopa; Macaca mulatta; Motor Activity; Nerve Growth Factors; Nerve Tissue Proteins; Neuroprotective Agents; Parkinson Disease, Secondary; Stereotyped Behavior

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease, Secondary; Quinolones; Quinpirole; Receptors, Dopamine D1; Thiophenes

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Drug Carriers; Injections, Intraperitoneal; Levodopa; Liposomes; Male; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Benzazepines; Dopamine Agonists; Haplorhini; Levodopa; Motor Activity; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine; Receptors, Dopamine D1

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cell Count; Chronic Disease; Disease Models, Animal; Disease Progression; Dopamine Agents; Levodopa; Macaca fascicularis; Movement; Neurons; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aminoquinolines; Animals; Caudate Nucleus; Dopamine Agonists; Enkephalins; Female; Imidazoles; In Situ Hybridization; Levodopa; Macaca fascicularis; Ovariectomy; Parkinson Disease, Secondary; Protein Precursors; Putamen; Receptors, Dopamine D2; RNA, Messenger; Transcription, Genetic

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Carbidopa; Catechols; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Levodopa; Male; Movement Disorders; Nitriles; Severity of Illness Index

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Bromocriptine; Callithrix; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; Motor Skills; Neurologic Examination; Parkinson Disease, Secondary; Receptors, Dopamine D2

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Macaca fascicularis; Male; Motor Skills; Neurologic Examination; Nicotinic Agonists; Parkinson Disease, Secondary; Pyridines; Pyrrolidines; Receptors, Cholinergic; Receptors, Nicotinic

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Injections, Subcutaneous; Levodopa; Macaca fascicularis; Neurologic Examination; Parkinson Disease, Secondary; Receptors, N-Methyl-D-Aspartate

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neurons; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Chronic Disease; Female; Globus Pallidus; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Parkinson Disease, Secondary

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Female; Levodopa; Locomotion; Macaca fascicularis; Movement Disorders; Parkinson Disease, Secondary; Receptors, Dopamine D1

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Animals; Benzopyrans; Callithrix; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Male; Quinolones; Receptors, Dopamine D1; Thiophenes

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Female; Levodopa; Locomotion; Macaca fascicularis; Parkinson Disease, Secondary; Purinergic P1 Receptor Antagonists; Purines; Receptor, Adenosine A2A

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2-Amino-5-phosphonovalerate; Animals; Antiparkinson Agents; Differential Threshold; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Drug Tolerance; Excitatory Amino Acid Antagonists; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; N-Methylaspartate; Sexual Behavior, Animal

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Mapping; Carbidopa; Dopamine Agents; Female; Levodopa; Linear Models; Macaca mulatta; Magnetic Resonance Imaging; Mathematics; Models, Statistical; Parkinson Disease, Secondary; Regression Analysis; Systems Analysis

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Attention; Cognition Disorders; Conditioning, Operant; Discrimination Learning; Dopamine Agents; Female; Levodopa; Macaca fascicularis; Macaca nemestrina; Male; Memory, Short-Term; Nicotine; Nicotinic Agonists; Pattern Recognition, Visual; Pyridines; Pyrrolidines; Receptors, Nicotinic; Space Perception

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agonists; Drug Interactions; Female; Levodopa; Macaca nemestrina; Motor Activity; Nicotine; Parkinson Disease, Secondary; Receptors, Dopamine D2; Rotation; Tetrahydronaphthalenes; Thiophenes

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Antiparkinson Agents; Binding Sites; Cerebellum; Dopamine Antagonists; Humans; Levodopa; Male; Models, Chemical; Occupational Diseases; Parkinson Disease, Secondary; Putamen; Receptors, Dopamine; Receptors, Serotonin; Severity of Illness Index; Spiperone; Tomography, Emission-Computed

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine Agents; Female; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Microdialysis; Parkinson Disease, Secondary; Treatment Outcome

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Antagonists; Animals; Antiparkinson Agents; Brain; Callithrix; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesias; Female; Idazoxan; Levodopa; Male; Receptors, Adrenergic, alpha-2; Time Factors; Yohimbine

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Electrophysiology; Eye Movements; Globus Pallidus; Levodopa; Macaca mulatta; Motor Activity; Neurons; Parkinsonian Disorders

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine; Animals; Antiparkinson Agents; Antipsychotic Agents; Caffeine; Catalepsy; Dopamine Agents; Hypokinesia; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Phenethylamines; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Purines; Reserpine; Theophylline

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Dopamine; Dopamine Agents; Drug Synergism; Drug Therapy, Combination; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Parkinson Disease

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine Agents; Female; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Neurologic Examination; Severity of Illness Index

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Electrophysiology; Female; Globus Pallidus; Levodopa; Macaca mulatta; Neurons; Neuroprotective Agents; Parkinson Disease, Secondary; Riluzole

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Callithrix; Carbidopa; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Purinergic P1 Receptor Antagonists; Purines; Quinpirole; Receptor, Adenosine A2A; Receptors, Dopamine D1; Receptors, Dopamine D2

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Behavior, Animal; Callithrix; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Hydrazines; Levodopa; Male; Motor Activity; Quinolones; Quinpirole; Thiophenes; Tyrosine

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzodiazepines; Dioxoles; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Parkinson Disease, Secondary; Piperidines; Receptors, AMPA; Severity of Illness Index

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Dopamine Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Haloperidol; Levodopa; Macaca mulatta; Male; Parkinson Disease, Secondary; Piperidines; Rats; Rats, Inbred F344; Reaction Time; Receptors, N-Methyl-D-Aspartate

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Corpus Striatum; Denervation; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Neurons; Parkinson Disease, Secondary; Receptors, Dopamine; Saimiri; Substantia Nigra

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Corpus Striatum; Diagnosis, Differential; Disease Models, Animal; Dopamine; Levodopa; Macaca fascicularis; Male; Multiple System Atrophy; Nerve Degeneration; Neurotoxins; Nitro Compounds; Parkinson Disease, Secondary; Propionates; Striatonigral Degeneration

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Binding Sites; Carrier Proteins; Caudate Nucleus; Dopamine Plasma Membrane Transport Proteins; Female; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Parkinsonian Disorders; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Saimiri; Substantia Nigra

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Carbidopa; Catheterization; Caudate Nucleus; Cell Line; Dependovirus; Dopamine; Drug Administration Routes; Drug Combinations; Fluorine Radioisotopes; Genetic Therapy; Genetic Vectors; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Neurons; Parkinson Disease, Secondary; Prodrugs; Putamen; Tomography, Emission-Computed; Tyrosine; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dopamine Agents; Excitatory Amino Acid Antagonists; Levodopa; Motor Activity; Parkinson Disease; Parkinson Disease, Secondary; Piperidines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain Chemistry; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Excitatory Amino Acid Antagonists; Iodine Radioisotopes; Levodopa; Parkinson Disease, Secondary; Radioligand Assay; Receptors, N-Methyl-D-Aspartate; Saimiri

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; alpha-Methyltyrosine; Animals; Antiparkinson Agents; Apomorphine; Benzopyrans; Callithrix; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Levodopa; Locomotion; Male; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Neural Inhibition; Neuropeptides; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Receptors, Dopamine; Receptors, GABA; Receptors, Glutamate; Signal Transduction

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Levodopa; Male; Mice; Mice, Inbred C57BL; Olfactory Bulb; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Piperidines; Receptors, Dopamine D2

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Clorgyline; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Motor Activity; Phenelzine; Phenethylamines; Selegiline; Thiazoles; Tryptamines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Benzazepines; Corpus Striatum; Decarboxylation; Dihydroxyphenylalanine; Dopamine; Dopamine Agents; Dopamine Antagonists; Levodopa; Male; Mice; Substantia Nigra

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carrier Proteins; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Electrophysiology; Female; Globus Pallidus; Levodopa; Macaca; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Parkinson Disease, Secondary; Radioligand Assay

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Levodopa; Male; Memantine; Mice; Mice, Inbred C57BL; Motor Activity; Parkinsonian Disorders; Recovery of Function

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Indoles; Levodopa; Neurologic Examination; Parkinsonian Disorders

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Apomorphine; Callithrix; Corpus Striatum; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Idazoxan; Levodopa; Male; Neurologic Examination; Neurons; Norepinephrine; Substantia Nigra

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Drug Therapy, Combination; Dyskinesias; Female; Hypokinesia; Levodopa; Male; Morphinans; Motor Activity; Naltrexone; Narcotic Antagonists; Parkinsonian Disorders; Posture; Receptors, Opioid, delta; Receptors, Opioid, mu

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Chronic Disease; Disability Evaluation; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Dyskinesias; Female; Image Processing, Computer-Assisted; Levodopa; Macaca mulatta; Motor Activity; Parkinsonian Disorders; Video Recording

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Avoidance Learning; Benserazide; Biogenic Monoamines; Brain Chemistry; Corpus Striatum; Dopamine; Dopamine Agents; Levodopa; Male; Memory Disorders; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Corpus Striatum; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Enkephalins; Female; Gene Expression Regulation; In Situ Hybridization; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Protein Precursors; RNA, Messenger; Saimiri; Substantia Nigra; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Cocaine; Dopamine Agents; Humans; Levodopa; Male; Methylphenidate; Mice; Mice, Inbred ICR; Organotechnetium Compounds; Parkinson Disease; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution; Tropanes

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Antiparkinson Agents; Bromocriptine; Carbidopa; Chlorocebus aethiops; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Electrodes, Implanted; Female; Globus Pallidus; Levodopa; Neurons; Organic Chemicals; Parkinsonian Disorders

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Motor Activity

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Arousal; Callithrix; Caudate Nucleus; Corpus Striatum; Culture Techniques; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dyskinesias; Female; In Situ Hybridization; Levodopa; Locomotion; Male; Piribedil; RNA, Messenger; Severity of Illness Index; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Female; Hyperkinesis; Levodopa; Male; Observer Variation; Random Allocation; Reproducibility of Results; Saimiri; Sensitivity and Specificity; Striatonigral Degeneration; Surveys and Questionnaires

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Callithrix; Dopamine; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; In Situ Hybridization; Levodopa; Male; Motor Activity; Naloxone; Narcotic Antagonists; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; RNA; Rotation; Stereotyped Behavior; Sympathectomy, Chemical

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bicuculline; Cholinergic Fibers; Female; GABA Antagonists; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Levodopa; Macaca mulatta; Male; Motor Activity; Neural Inhibition; Neural Pathways; Parkinsonian Disorders; Pons; Receptors, GABA-A; Recovery of Function; Tegmentum Mesencephali; Treatment Outcome

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Behavior, Animal; Dibenzothiazepines; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Quetiapine Fumarate; Rats; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Antagonists

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dystonia; Female; Levodopa; Macaca fascicularis; Neurotoxins; Nitro Compounds; Parkinsonian Disorders; Propionates; Putamen; Striatonigral Degeneration; Substantia Nigra

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Callithrix; Corpus Striatum; Dose-Response Relationship, Drug; Dronabinol; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Globus Pallidus; Levodopa; Male; Motor Skills; Parkinsonian Disorders; Receptors, Cannabinoid; Receptors, Drug

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Motor Skills; Neurologic Examination; Parkinsonian Disorders; Recurrence

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinsonian Disorders; Pergolide; Receptors, Dopamine D1; Receptors, Dopamine D2; Severity of Illness Index

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Binding, Competitive; Chronic Disease; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Enkephalins; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neural Pathways; Neurons; Parkinsonian Disorders; Protein Precursors; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Substantia Nigra; Tachykinins; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Carbidopa; Catechols; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Male; Nitriles; Parkinsonian Disorders; Pulse Therapy, Drug; Substantia Nigra; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acrylamides; Animals; Antiparkinson Agents; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; Haplorhini; Humans; Isoquinolines; Levodopa; Molecular Structure; Motor Activity; MPTP Poisoning; Naphthalenes; Neostriatum; Piperazines; Pyrrolidines; Rats; Receptors, Dopamine D2; Receptors, Dopamine D3

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dehydroepiandrosterone; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Female; Functional Laterality; Levodopa; Macaca fascicularis; Motor Activity; Ovariectomy; Parkinson Disease, Secondary

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Magnesium Sulfate; Motor Activity; Parkinsonian Disorders

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Ditiocarb; Dopamine; Drug Synergism; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Motor Activity; Parkinsonian Disorders; Reaction Time; Recovery of Function; Selegiline; Serotonin

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Parkinsonian Disorders; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Appetite; Behavior, Animal; Blinking; Dopamine Agents; Dyskinesia, Drug-Induced; Facial Expression; Feeding Behavior; Levodopa; Macaca fascicularis; Male; Motor Activity; Motor Skills; Parkinson Disease, Secondary; Postural Balance; Posture; Time Factors; Tremor

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Endorphins; Female; Levodopa; Macaca fascicularis; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2; Synaptic Transmission

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Basal Ganglia; Brain; Brain Chemistry; Dopamine Agents; Female; Iron; Iron Overload; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Parkinson Disease, Secondary; Prefrontal Cortex; Pregnancy; Weight Gain

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Apomorphine; Denervation; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Purines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Dopamine D1; Receptors, Dopamine D2; Sympatholytics

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Antiparkinson Agents; Callithrix; Dopamine Agents; Drug Synergism; Drug Therapy, Combination; Female; Indoles; Levetiracetam; Levodopa; Male; Parkinsonian Disorders; Piracetam

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Autoradiography; Behavior, Animal; Benzopyrans; Carbidopa; Cocaine; Dopamine Agents; Dopamine Agonists; Dopamine Antagonists; Dopamine Plasma Membrane Transport Proteins; Female; Grooming; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Nerve Tissue Proteins; Oxazines; Pyrroles; Radiopharmaceuticals; Receptors, Dopamine D2; Receptors, Dopamine D3; Stereotyped Behavior

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzopyrans; Brain; Callithrix; Disease Models, Animal; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Indoles; Levodopa; Parkinsonian Disorders; Pyrroles; Receptors, Dopamine D2; Receptors, Dopamine D3

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkaloids; Amino Acid Sequence; Animals; Antibodies; Autoradiography; Azocines; Brain; Bridged Bicyclo Compounds, Heterocyclic; Cell Membrane; Cerebral Cortex; Corpus Striatum; Humans; Iodine Radioisotopes; Levodopa; Molecular Sequence Data; Nicotine; Protein Subunits; Pyridines; Quinolizines; Receptors, Nicotinic; Saimiri

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Glycine Agents; Levodopa; Macaca mulatta; Motor Activity; Parkinsonian Disorders; Pilot Projects; Psychomotor Performance; Receptors, Glycine

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Carbidopa; Catechols; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Injections, Subcutaneous; Levodopa; Locomotion; Male; MPTP Poisoning; Nitriles; Severity of Illness Index; Substantia Nigra; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Blotting, Western; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinases; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Guanosine 5'-O-(3-Thiotriphosphate); Immunohistochemistry; In Situ Hybridization; Isotopes; Levodopa; Macaca fascicularis; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Nerve Tissue Proteins; Nortropanes; Parkinsonian Disorders; Phosphoproteins; Radioligand Assay; Receptors, Dopamine D1; Receptors, Dopamine D2; Signal Transduction; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Blotting, Western; Brain Chemistry; Bromocriptine; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Interactions; Hindlimb Suspension; Immobility Response, Tonic; Immunohistochemistry; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Motor Activity; Nerve Tissue Proteins; Selegiline; Time Factors; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Calbindins; Callithrix; Corpus Striatum; Disability Evaluation; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Female; Immunohistochemistry; Levodopa; Male; Motor Activity; Neurons; S100 Calcium Binding Protein G; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesias; Female; Levodopa; Macaca fascicularis; Motor Activity; Naltrexone; Narcotic Antagonists; Ovariectomy; Parkinsonian Disorders; Statistics, Nonparametric; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Blotting, Western; Brain; Callithrix; Diagnostic Imaging; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Immunoradiometric Assay; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Nerve Tissue Proteins; Neurofilament Proteins; Protein Subunits; Rats; Receptors, N-Methyl-D-Aspartate; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Immunohistochemistry; Levodopa; Male; Motor Activity; Movement Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Antagonists; Excitatory Amino Acid Transporter 2; Glutamic Acid; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Microdialysis; Microscopy, Immunoelectron; Substantia Nigra; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nerve Degeneration; Nociceptin; Opioid Peptides; Parkinson Disease; Rats; Rats, Sprague-Dawley; Synaptic Transmission

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dehydroepiandrosterone; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Severity of Illness Index

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Chorea; Disease Models, Animal; Female; Histamine Agonists; Levodopa; Parkinson Disease; Receptors, Histamine H3

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzoxazoles; Denervation; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Image Processing, Computer-Assisted; In Situ Hybridization; Levodopa; Macaca fascicularis; Motor Activity; Neuroprotective Agents; Oligonucleotide Probes; Ovariectomy; Parkinson Disease, Secondary; Piperidines; Pyrimidines; Receptor, Adenosine A2A; Receptors, N-Methyl-D-Aspartate; Triazoles

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Dependovirus; Gene Expression; Genetic Therapy; Humans; Immunohistochemistry; Levodopa; Macaca mulatta; Male; Positron-Emission Tomography; Primate Diseases; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Corpus Striatum; Drug Interactions; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression Regulation; In Situ Hybridization; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Protein Precursors; Radioligand Assay; Receptors, Opioid; Regression Analysis; RNA, Messenger; Subthalamic Nucleus

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzothiazoles; Callithrix; Data Interpretation, Statistical; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Piperazines; Pramipexole; Pyridines; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Serotonin Antagonists; Serotonin Receptor Agonists

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Grooming; Hallucinations; Levodopa; Parkinsonian Disorders; Psychomotor Agitation; Psychotic Disorders; Statistics, Nonparametric; Stereotyped Behavior

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Dopamine Agonists; Drug Administration Routes; Drug Administration Schedule; Levodopa; Mental Disorders; Parkinsonian Disorders; Severity of Illness Index; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; Motor Activity

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Male; Models, Biological; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Protein Kinase C; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Animals; Disease Models, Animal; Dopamine Agents; Hyperkinesis; Levodopa; Male; Mice; Mice, Inbred C57BL; Movement; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Hypnotics and Sedatives; Levodopa; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Saimiri; Vomiting

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; Benserazide; Callithrix; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Infusions, Intravenous; Levodopa; Locomotion; Male; Motor Activity; MSH Release-Inhibiting Hormone; Parkinsonian Disorders

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Azetidines; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Male; Molecular Structure; Parkinson Disease; Receptor, Cannabinoid, CB1; Triazines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Catechols; Dopamine Agents; Dopamine Agonists; Drug Administration Schedule; Drug Synergism; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; Motor Activity; Nitriles

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Circadian Rhythm; Dyskinesia, Drug-Induced; Levodopa; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Saimiri; Substantia Nigra; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dyskinesia, Drug-Induced; Functional Laterality; Intralaminar Thalamic Nuclei; Kainic Acid; Levodopa; Macaca fascicularis; Male; Parkinsonian Disorders; Stereotaxic Techniques

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Analysis of Variance; Animals; Behavior, Animal; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cytosol; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Doxycycline; Functional Laterality; Levodopa; Mice; Mice, Transgenic; Microscopy, Electron, Transmission; Nerve Degeneration; Neurotoxins; Oxidative Stress; Prosencephalon; Psychomotor Performance; Silver Staining

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; Animals; Chromatin; Chromosome Aberrations; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Female; Histones; Levodopa; Macaca mulatta; Male; Methylation; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Phosphorylation; Protein Processing, Post-Translational; Species Specificity

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Injections, Intra-Arterial; Injections, Intravenous; Levodopa; Macaca fascicularis; Macaca mulatta; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Primates; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Species Specificity

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Biperiden; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Female; Levodopa; Macaca nemestrina; Muscarinic Antagonists; Parkinsonian Disorders; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Tetrahydronaphthalenes; Thiophenes

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Pyridines; Receptors, N-Methyl-D-Aspartate; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Treatment Outcome

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic alpha-Antagonists; Animals; Benserazide; Brain Injuries; Dihydroxyphenylalanine; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Prazosin; Receptors, Adrenergic, alpha

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Denervation; Dopamine Agonists; Heart; Humans; Hypotension, Orthostatic; Levodopa; Male; Methamphetamine; Mice; Mice, Inbred C57BL; Neurotoxins; Norepinephrine; Parkinson Disease

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzopyrans; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Organic Chemicals; Ovariectomy; Parkinsonian Disorders; Serotonin Receptor Agonists

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antibodies; Antiparkinson Agents; Apomorphine; Chemokine CX3CL1; Disease Models, Animal; DNA Nucleotidylexotransferase; Dose-Response Relationship, Drug; Drug Interactions; Gene Expression Regulation; Levodopa; Male; Mental Disorders; Nerve Tissue Proteins; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reaction Time; Stereotyped Behavior; Substantia Nigra; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; CD11b Antigen; Conditioning, Operant; Disease Models, Animal; Dose-Response Relationship, Drug; Glial Fibrillary Acidic Protein; Jaw; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Movement; Mucuna; Neuroprotective Agents; Oxidopamine; Parasympathomimetics; Parkinson Disease; Phytotherapy; Rats; Rats, Sprague-Dawley; Seeds; Sympatholytics; Tacrine; Time Factors; Vibrissae

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Blood-Brain Barrier; Brain; Dyskinesia, Drug-Induced; Gadolinium DTPA; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Ascorbic Acid; Brain; Central Nervous System Depressants; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agents; Ferrous Compounds; Levodopa; Male; Melatonin; Mice; Mice, Inbred BALB C; Oxidopamine; Parkinsonian Disorders

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cell Membrane; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Neostriatum; Neurons; Parkinsonian Disorders; Receptors, AMPA; Synapses; Synaptic Vesicles

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenine; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Brain Chemistry; CD11b Antigen; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Early Growth Response Protein 1; Gene Expression Regulation; Jaw; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Movement; Nerve Degeneration; Nerve Tissue Proteins; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotarod Performance Test; Time Factors; Triazoles; Vibrissae

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult Stem Cells; Animals; Bromodeoxyuridine; Cell Count; Cell Death; Cell Division; Dopamine; Dopamine Agents; Hippocampus; Homeodomain Proteins; Levodopa; Male; Mice; Mice, Inbred C57BL; Neural Cell Adhesion Molecule L1; Neurogenesis; Proliferating Cell Nuclear Antigen; Sialic Acids; Time Factors; Tumor Suppressor Proteins; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Callithrix; Carbidopa; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Female; Levodopa; Male; Methyldopa; Motor Activity; Movement Disorders

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Dose-Response Relationship, Drug; Dyskinesias; Endocytosis; G-Protein-Coupled Receptor Kinases; Gene Knockdown Techniques; Genetic Therapy; Humans; Lentivirus; Levodopa; Macaca; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotation; Signal Transduction

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antiparkinson Agents; Cell Count; Disease Models, Animal; Dopamine; Drug Interactions; Gene Expression Regulation; Homovanillic Acid; Levodopa; Male; Movement; Neurons; Neurotoxins; Parkinsonian Disorders; Rats; Rats, Wistar; Reaction Time; Substantia Nigra; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Levodopa; Male; Medial Forebrain Bundle; Mice; Mice, Inbred BALB C; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Salicylates

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopamine; Dopamine Agents; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Levodopa; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Inbred C57BL; Neurotoxins; Protons

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Area Under Curve; Benzoxazoles; Callithrix; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Motor Activity; Movement Disorders; Piperazines; Statistics, Nonparametric; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Neuronal Plasticity; Oxidopamine; Parkinson Disease; Presynaptic Terminals; Radioligand Assay; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Carotid Arteries; Conditioning, Operant; Corpus Striatum; Dihydroxyphenylalanine; Dopamine Agents; Dyskinesia, Drug-Induced; Dystonia; Female; Injections, Intravenous; Levodopa; Macaca mulatta; MPTP Poisoning; Parkinson Disease, Secondary; Psychomotor Performance; Radionuclide Imaging; Radiopharmaceuticals; Substantia Nigra

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Artemia; Biological Assay; Biotransformation; Electron Transport Complex I; Glutathione Transferase; Herbicides; Inactivation, Metabolic; Levodopa; Rotenone

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Female; Levodopa; Macaca mulatta; Parkinson Disease, Secondary; Protein Binding; Tomography, Emission-Computed, Single-Photon

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Biogenic Amines; Brain; Cabergoline; Dopamine Agents; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Ketanserin; Levodopa; Macaca; Parkinsonian Disorders; Receptor, Serotonin, 5-HT2A

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Colorimetry; DNA Primers; Dopamine; Dyskinesia, Drug-Induced; Fluorescent Antibody Technique; GABAergic Neurons; Globus Pallidus; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; In Situ Hybridization, Fluorescence; Levodopa; Macaca fascicularis; Male; Neurons, Efferent; Parkinsonian Disorders; Polymerase Chain Reaction; Statistics, Nonparametric; Thalamus; Vesicular Glutamate Transport Protein 1

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cyclohexanols; Disease Models, Animal; Dopamine Antagonists; Drug Synergism; Haloperidol; Levodopa; Mice; Mice, Inbred C57BL; Molecular Conformation; Motor Activity; Neurotoxins; Parkinson Disease; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Neurotransmitter; Stereoisomerism

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; alpha-Methyltyrosine; Analysis of Variance; Animals; Brain; Choline O-Acetyltransferase; Chromatography, High Pressure Liquid; Dendrites; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Plasma Membrane Transport Proteins; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Functional Laterality; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Glutamate Decarboxylase; Humans; Levodopa; Macaca fascicularis; Male; Medial Forebrain Bundle; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Immunoelectron; Middle Aged; Nerve Growth Factors; Organic Chemicals; Oxidopamine; Parkinsonian Disorders; Postmortem Changes; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Tandem Mass Spectrometry

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Dopamine; Female; Gene Expression Regulation; Levodopa; Mice; Mice, Inbred C57BL; Parkinson Disease; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Antiparkinson Agents; Basal Ganglia; Biological Clocks; Brain Waves; Disease Models, Animal; Dopamine; Electric Stimulation; Functional Laterality; Globus Pallidus; Levodopa; Macaca; Male; MPTP Poisoning; Neurons; Statistics, Nonparametric; Subthalamic Nucleus

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Environment; Gene Expression Regulation; Levodopa; Mice; Mice, Inbred C57BL; Motor Activity; Parkinson Disease; Psychomotor Performance; Substantia Nigra; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Drug Interactions; Dyskinesias; Female; Levodopa; Macaca; Male; Motor Activity; Parkinson Disease; Pyridines; Pyrroles; Receptors, Dopamine D4

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzodioxoles; Biogenic Monoamines; Callithrix; Dose-Response Relationship, Drug; Female; Levodopa; Methylamines; Motor Activity; Movement Disorders; Neurotransmitter Uptake Inhibitors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2',3'-Cyclic-Nucleotide Phosphodiesterases; Adult Stem Cells; Analysis of Variance; Animals; Antigens; Bromodeoxyuridine; Calcium-Binding Proteins; Cells, Cultured; Disease Models, Animal; Dopamine; Dopamine Agents; Environment; Female; Green Fluorescent Proteins; Intermediate Filament Proteins; Levodopa; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microfilament Proteins; Motor Activity; MPTP Poisoning; Nerve Tissue Proteins; Nestin; Proteoglycans; Substantia Nigra; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopaminergic Neurons; Fluorescent Antibody Technique; Levodopa; Macaca fascicularis; Male; Neostriatum; Phenotype; Substantia Nigra; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Cognition Disorders; Conditioning, Operant; Disease Models, Animal; Levodopa; Macaca fascicularis; Male; Movement; MPTP Poisoning; Photic Stimulation; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antioxidants; Antiparkinson Agents; Behavior, Animal; Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Disease Models, Animal; Dopamine Agents; Dyskinesias; Immunohistochemistry; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Neurons; Oxidative Stress; Parkinson Disease; Positron-Emission Tomography; Thiazoles

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine; Dopamine Agents; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Parkinsonian Disorders; Receptors, Dopamine D1; Rotarod Performance Test; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Homeodomain Proteins; Levodopa; Male; Maneb; Metalloporphyrins; Mice; Microglia; Minocycline; Mitochondria; Paraquat; Parkinson Disease, Secondary; Proteome; Stathmin; Superoxide Dismutase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Basal Ganglia; Behavior, Animal; Benzamides; Brain; Case-Control Studies; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Parkinson Disease; Pyridines; Receptor, Serotonin, 5-HT1B; Serotonin; Sulfonamides; Thiazoles

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Caudate Nucleus; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Levodopa; Macaca fascicularis; Male; Parkinsonian Disorders; Putamen; Receptor, Adenosine A2A; Receptor, Cannabinoid, CB1; Receptors, Dopamine D2

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Allosteric Regulation; Animals; Antiparkinson Agents; Biological Availability; Cell Membrane Permeability; Dogs; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Hypersensitivity, Delayed; Levodopa; Macaca fascicularis; Madin Darby Canine Kidney Cells; Male; Microsomes, Liver; Models, Molecular; Parkinson Disease; Pyrazines; Pyrazoles; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Structure-Activity Relationship

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Levodopa; Macaca mulatta; Male; Parkinson Disease

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Levodopa; Macaca fascicularis; MAP Kinase Signaling System; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Hypokinesia; Levodopa; Macaca mulatta; Male; Morphine; Motor Activity; Parkinson Disease; Postural Balance; Tremor

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease; Tryptophan

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catechol O-Methyltransferase; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Levodopa; Male; Methylation; Mice; Mice, Inbred C57BL; Oxidation-Reduction; Parkinsonian Disorders; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Homovanillic Acid; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Protein Binding; Pyridines; Serotonin

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Random Allocation

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Callithrix; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Female; Indoles; Levodopa; Male; Motor Activity; Pergolide; Purines; Receptor, Adenosine A2A

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopaminergic Neurons; Drug Synergism; Levodopa; Male; Melatonin; Mice; Mice, Inbred BALB C; Neuroprotective Agents; Parkinsonian Disorders; Substantia Nigra

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Benzylidene Compounds; Cells, Cultured; Disease Models, Animal; Levodopa; Male; Membrane Potential, Mitochondrial; Mesencephalon; Mice; Mice, Inbred C57BL; Mitochondria; Mitochondrial Proteins; MPTP Poisoning; Neuroblastoma; Neurons; Neuroprotective Agents; Neurotoxins; Psychomotor Performance; rho GTP-Binding Proteins; Thiazolidinediones; Time Factors; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arrestins; Behavior, Animal; beta-Arrestins; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Gene Deletion; Levodopa; Macaca; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction; Up-Regulation

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca; Parkinsonian Disorders; Receptors, Glutamate; Subthalamic Nucleus

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Animals; Antigens, Neoplasm; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Dose-Response Relationship, Drug; Electron Transport Complex I; Exploratory Behavior; Gene Expression Regulation; Levodopa; Male; Mice; Mice, Knockout; Mitochondria; Motor Activity; Oxygen Consumption; Psychomotor Performance; Substantia Nigra; Synaptosomes; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Nicotinic Agonists; Parkinsonian Disorders; Saimiri; Substantia Nigra

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood-Brain Barrier; Brain; Disease Models, Animal; Dopamine; Levodopa; Macaca; Male; Parkinson Disease; Parkinson Disease, Secondary; Permeability; Pyridines

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Combinations; Hydrazines; Levodopa; Male; Mice, Inbred C57BL; Motor Activity; Neuroprotective Agents; Oxadiazoles; Oxidative Stress; Parkinson Disease; Substantia Nigra; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antiparkinson Agents; Bungarotoxins; Case-Control Studies; Caudate Nucleus; Corpus Striatum; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Gene Expression; Humans; Iodine Radioisotopes; Levodopa; Macaca fascicularis; Male; Organ Specificity; Ovariectomy; Parkinson Disease; Parkinson Disease, Secondary; Putamen; Pyridines; Signal Transduction

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drinking; Drug Administration Schedule; Drug Delivery Systems; Eating; Female; Injections, Intramuscular; Levodopa; Neurotoxins; Parkinsonian Disorders; Severity of Illness Index; Swine; Swine, Miniature; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dopamine; Extracellular Signal-Regulated MAP Kinases; Gynostemma; Humans; Levodopa; Male; Memory; Mice; Mice, Inbred C57BL; Parkinson Disease; Plant Extracts; Protective Agents; Substantia Nigra

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Enkephalins; Extracellular Signal-Regulated MAP Kinases; Levodopa; Magnoliopsida; Male; Mice, Inbred C57BL; Movement; Parkinson Disease; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-fos; Substance P

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Benzothiazoles; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Drug Combinations; Levodopa; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Parkinsonian Disorders; Pramipexole; Selegiline

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; Gynostemma; Levodopa; Male; Maze Learning; Memory Disorders; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Plant Extracts; Spatial Memory

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Electroacupuncture; Female; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Motor Activity; Motor Cortex; Parkinson Disease; Parkinson Disease, Secondary

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Gene Expression Regulation; Levodopa; Male; Mice, Inbred C57BL; Motor Activity; Parkinson Disease; Physical Conditioning, Animal; RNA, Messenger; Signal Transduction; Substantia Nigra; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Basal Ganglia; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Gene Expression Regulation; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Phosphopyruvate Hydratase; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Glucagon-Like Peptide 1; Levodopa; Linagliptin; Mice; Mice, Inbred BALB C; NF-kappa B; Parkinsonian Disorders; Toll-Like Receptor 4; Transforming Growth Factor beta1

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Parkinsonian Disorders; Piperazines; Psychoses, Substance-Induced; Triazoles

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dependovirus; Drug Evaluation, Preclinical; Female; Genes, Reporter; Genes, Synthetic; Genetic Vectors; GTP Cyclohydrolase; Humans; Levodopa; Macaca mulatta; Male; Motor Activity; Parkinsonian Disorders; Pars Compacta; Proof of Concept Study; Putamen; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catalepsy; Haloperidol; Harmine; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Rats

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dyskinesias; HSP27 Heat-Shock Proteins; Levodopa; Macaca fascicularis; Male; Norepinephrine; Phosphorylation; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cognition; Disease Models, Animal; Levodopa; Parkinson Disease; Primates

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Blood-Brain Barrier; Cell Death; Cognitive Dysfunction; Disease Models, Animal; Dopaminergic Neurons; Fatty Acid Binding Protein 3; Levodopa; Ligands; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neuroprotective Agents; Parkinson Disease; Protein Aggregation, Pathological

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Infusions, Intraventricular; Levodopa; Macaca; Male; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Pilot Projects

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disabled Persons; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Motor Disorders; Parkinson Disease; Receptors, Metabotropic Glutamate

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Callithrix; Disease Models, Animal; Female; Levodopa; Male; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motor Activity; Parkinsonian Disorders

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Callithrix; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motor Activity; Parkinsonian Disorders; Psychoses, Substance-Induced

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Catechol O-Methyltransferase Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Erythrocytes; Female; Levodopa; Locomotion; Macaca fascicularis; Oxadiazoles; Parkinsonian Disorders; Time Factors

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain; Dopamine Agents; Female; Levodopa; Macaca mulatta; Neurons; Parkinsonian Disorders

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Bromocriptine; Chlorocebus aethiops; Disease Models, Animal; Dopamine Agonists; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Phenanthridines; Receptors, Dopamine D1; Receptors, Dopamine D2

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Female; Levodopa; Male; Parkinsonian Disorders; Psychotic Disorders

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Bridged Bicyclo Compounds; Callithrix; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; Parkinsonian Disorders; Piperazines; Psychotic Disorders; Pyridines; Receptors, Metabotropic Glutamate; Serotonin 5-HT2 Receptor Antagonists; Sulfonamides

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dyskinesia, Drug-Induced; Humans; Inflammation; Levodopa; Macaca fascicularis; Parkinson Disease; Pyridines; Receptor, Metabotropic Glutamate 5

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Levodopa; Mice; Mice, Inbred C57BL; MPTP Poisoning; Parkinson Disease; Retina; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Creatine; Curcumin; Disease Models, Animal; Gastrointestinal Microbiome; Levodopa; Metabolome; Methionine; Mice; Mice, Inbred C57BL; Neuroinflammatory Diseases; Neuroprotective Agents; Parkinson Disease; RNA, Ribosomal, 16S; Sarcosine

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Disease Models, Animal; Dopamine; Drugs, Chinese Herbal; Levodopa; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Glycine; Levodopa; Macaca fascicularis; Neuroprotective Agents; Parkinsonian Disorders; Pilot Projects; Prodrugs; Receptors, N-Methyl-D-Aspartate

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Drug Inverse Agonism; Levodopa; Motor Activity; Parkinson Disease; Receptor, Adenosine A2A